ROLE OF 5-HT4 RECEPTORS IN THE MOUSE PASSIVE AVOIDANCE TEST by Galeotti, Nicoletta et al.
Role of 5-HT4 Receptors in the Mouse Passive
Avoidance Test1
NICOLETTA GALEOTTI, CARLA GHELARDINI and ALESSANDRO BARTOLINI
Department of Preclinical and Clinical Pharmacology, Viale G.B. Morgagni 65, I-50134 Florence, Italy
Accepted for publication April 9, 1998 This paper is available online at http://www.jpet.org
ABSTRACT
The effects of the administration of different 5-HT4 receptor
antagonists (SDZ 205557, GR 125487) and 5-HT4 receptor
agonists (BIMU 1, BIMU 8) on memory processes were evalu-
ated in the mouse passive avoidance test. The administration of
SDZ 205557 (10 mg kg21 i.p.) and GR 125487 (10 mg kg21 i.p.)
immediately after termination of the training session produced
an amnesic effect. BIMU 1 (20 mg kg21 i.p.) and BIMU 8 (30 mg
kg21 i.p.), administered 20 min before the training session,
prevented the 5-HT4 receptor antagonist-induced amnesia. In
the same experimental conditions BIMU 1 (10 mg kg21 i.p.; 25
mg/mouse intracerebroventricularly) and BIMU 8 (30 mg kg21
i.p.; 30 mg per mouse intracerebroventricularly) prevented sco-
polamine (1 mg kg21 i.p.) and dicyclomine (2 mg kg21 i.p.)
amnesia and, at the dose of 10 and 30 mg kg21 i.p. respec-
tively, prevented amnesia induced by exposure to a hypoxic
environment. At the highest effective doses, none of the drugs
impaired motor coordination, as revealed by the rota rod test,
or modified spontaneous motility and inspection activity, as
revealed by the hole board and Animex tests. The 5-HT3 an-
tagonist ondansetron (0.1–1 mg kg21 i.p.) was unable to pre-
vent scopolamine-, 5-HT4 antagonist- and hypoxia-induced
amnesia. These results suggest that the modulation of 5-HT4
receptors plays an important role in the regulation of memory
processes. On these bases, the 5-HT4 receptor agonists could
be useful in the treatment of cognitive deficits although 5-HT4
receptor antagonists may represent pharmacological tools for
investigation of new potential antiamnesic drugs.
The regulation of synaptic plasticity, which is fundamental
in learning and memory, involves long-term modulation of
ion-channel activity. Stimulation of 5-HT4 receptors may ini-
tiate this process by activation of adenylate cyclase. It has
been reported that stimulation of 5-HT4 receptors increases
intracellular cyclic AMP levels in mouse colliculi neurones
(Dumuis et al., 1988), guinea pig hippocampus (Bockaert et
al., 1990) and human prefrontal cortex (Monferini et al.,
1993) which then modulates the activity of protein kinase A
(Fagni et al., 1992; Ansanay et al., 1995). In rat hippocampus
and in mouse colliculi neurones, activation of protein kinase
A closes potassium channels. Therefore, reduced after-hyper-
polarization may increase neuronal excitability and ulti-
mately neurotransmitter release (Ansanay et al., 1995). Even
short exposures (1–2 sec) to 5-HT4 receptor agonists induce
long-lasting (2 hr) inhibition of inward potassium currents.
Early studies demonstrated the ability of metoclopramide,
a weak 5-HT4 receptor agonist, to prevent dicyclomine-in-
duced amnesia in the mouse passive avoidance test (Galeotti
et al., 1993). Fontana et al. (1994), using RS66331, a 5-HT3
receptor antagonist and 5-HT4 receptor agonist, have re-
ported ameliorative effects in the rat spatial memory test in
which this compound reverted performance deficit produced
by atropine as well as cognitive impairment of aged rats
when given alone. This findings are corroborated by experi-
ments using more selective 5-HT4 receptor agonists. Admin-
istration of RS67333, a highly selective 5-HT4 receptor ago-
nist, suppresses the rat performance deficit induced by
atropine in the Morris water maze, an effect also reversed by
the selective 5-HT4 receptor antagonist RS 67532 (Fontana et
al., 1997). Furthermore, (R)-zacopride, a weak 5-HT4 recep-
tor agonist with low affinity for 5-HT3 receptors, exerts
marked procognitive activity (Barnes et al., 1990). However,
the mechanism underlying this effect of (R)-zacopride is not
completely clear, considering the lack of effect of the more
selective 5-HT4 receptor agonist (S)-zacopride (Barnes et al.,
1990).
BIMU 1 and BIMU 8 are two benzimidazolones endowed
with 5-HT4 receptor agonistic and 5-HT3 receptor antagonis-
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tic properties (Dumuis et al., 1989, 1991; Turconi et al., 1990,
1991). Recent findings suggested that these compounds have
also affinity for s2 receptors (Bonhaus et al., 1994; Weather-
spoon et al., 1997). BIMU 1 showed about 1000-fold lower
affinity for other serotonin (5-HT1A, 5-HT2A, 5-HT2C), dopa-
mine (D1 and D2) and muscarinic (M1, M2, M3 and M4)
receptors (Bonhaus et al., 1993). Furthermore, the com-
pounds labeled SDZ 205557 and GR 125487 have been re-
ported as selective 5-HT4 receptor antagonists (Buchheit et
al., 1991; Gale et al., 1994). By using both the above-men-
tioned 5-HT4 receptor agonists (BIMU 1 and BIMU 8) and
antagonists (SDZ 205557 and GR 125487), the role of the
5-HT4 receptors in the modulation of learning and memory
processes was investigated in different passive avoidance
paradigms.
Methods
Animals. Male Swiss albino mice (23–30 g) from Morini (San Polo
d’Enza, Italy) were used. The mice were housed 15 per cage. The
cages were placed in the experimental room 24 hr before the test for
adaptation. The animals were fed a standard laboratory diet and tap
water ad libitum and kept at 23 6 1°C with a 12-hr light/dark cycle,
light on at 7 A.M. All experiments were carried out according to the
guidelines of the European Community Council for experimental
animal care.
Passive-avoidance test. The test was performed according to
the step-through method described by Jarvik and Kopp (1967). The
apparatus consists of a two-compartment acrylic box with a lighted
compartment connected to a darkened one by a guillotine door. Mice,
as soon as they entered the dark compartment, received a punishing
electrical shock (0.5 mA, 1 sec). The latency times for entering the
dark compartment were measured in the training test and after 24
hr in the retention test. For memory disruption, mice were either
exposed to a hypoxic environment (5%O2 in water-saturated nitro-
gen) for 8 min up to 30 sec before passive avoidance training or i.p.
injected with amnesic drugs. BIMU 1, BIMU 8, ondansetron, phy-
sostigmine and piracetam were injected 20 min before the training
session while scopolamine, dicyclomine, GR 125487 and SDZ 205557
were injected immediately after termination of the training session.
The maximum entry latency allowed in the retention session was 120
sec. The deficit in passive avoidance performance was expressed as
the difference (in seconds) between retention and training latencies.
Hole board test. The hole board test uses a 40 cm square plane
with 16 flush-mounted cylindrical holes (diameter 3 cm) distributed
4 by 4 in an equidistant, grid-like manner. The mice were placed in
the center of the board one by one and left to move about freely for a
period of 5 min each. Two photoelectric beams, crossing the plane
from mid-point to mid-point of opposite sides, thus dividing the plane
into four equal quadrants, automatically signaled the movement of
the animals on the surface of the plane. Miniature photoelectric cells,
in each of the 16 holes, recorded the exploration of the holes (head
plunging activity) by the mice.
Rota rod test. The apparatus consists of a base platform and a
rotating rod of 3-cm diameter with a non-skid surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in length,
was divided into five equal sections by six disks. Thus up to five mice
were tested simultaneously on the apparatus, with a rod-rotation
speed of 16 r.p.m. The integrity of motor coordination was assessed
on the basis of the number of falls from the rod in 30 sec, according
to Vaught et al. (1985). Performance time was measured before and
15, 30 and 45 min after s.c. administration of the drugs.
Spontaneous activity meter (Animex). Locomotor activity in
mice was quantified using an Animex activity meter Type S (LKB,
Farad, Sweden) set to maximum sensitivity. Mice were placed on the
top of the Animex activity meter and each movement produced a
signal due to variation in inductance and capacity of the apparatus
resonance circuit. These signals were automatically converted to
numbers. On the day of the experiment the mice were treated and
then the cage, containing five mice, was put on the measurement
platform. Activity counts were made every 15 min for 45 min starting
immediately after injection of the drug. Because of the arbitrary
scale adopted to quantify movements, drug-treated mice were always
compared with saline-treated ones.
i.c.v. injection technique. i.c.v. administration was performed
under ether anesthesia with isotonic saline as a solvent, according to
the method described by Haley and McCormick (1957). During an-
esthesia, mice were grasped firmly by the loose skin behind the head.
A hypodermic needle (0.4-mm external diameter) attached to a 10-ml
syringe was inserted perpendicularly through the skull and no more
than 2 mm into the brain of the mouse, where 5 ml of drug were then
administered. The injection site was 1 mm to the right or left from
the midpoint on a line drawn through to the anterior base of the ears.
Injections were performed randomly into the right or left ventricle.
To ascertain that the drugs were administered exactly into the
cerebral ventricle, some mice were injected with 5 ml of 1:10 diluted
India ink and their brains were examined macroscopically after
sectioning. The accuracy of the injection technique was evaluated
and the percentage of correct injections was 95.
Drugs. The following drugs were used: BIMU 1, BIMU 8, GR
125487, ondansetron (Boehringer Ingelheim, Milan, Italy), SDZ
205557 prepared in the Department of Pharmaceutical Sciences of
University of the Florence according to the method described by
Romanelli et al. (1993); D-amphetamine (De Angeli, Florence, Italy);
scopolamine hydrobromide, physostigmine hemisulphate, piracetam
(Sigma); dicyclomine hydrochloride (Le Petit).
Drugs were dissolved in isotonic (NaCl 0.9%) saline solution im-
mediately before use. Drug concentrations were prepared so that the
necessary dose could be administered in a volume of 5 ml/mouse by
i.c.v. injection and 10 ml kg21 by i.p. injection.
Statistical analysis. All experimental results are given as the
means 6 S.E.M. Analysis of variance, followed by Fisher’s protected
least significant difference procedure for post hoc comparison, was
used to verify significance between two means. Data were analysed
with the StatView software for the Macintosh (1992). P , .05 were
considered significant.
Results
Amnesic effect of 5-HT4 antagonists. The dose response
curves for SDZ 205557 (1–20 mg kg21 i.p.) and GR 125487
(0.1–20 mg kg21 i.p.) in the mouse passive avoidance test are
reported in figure 1. The two compounds, injected immedi-
ately after the training session, produced deficits in passive-
avoidance behavior. This effect was dose-dependent and sta-
tistical significance was reached at the dose of 10 mg kg21 i.p.
Higher doses of SDZ 205557 and GR 125487 were not inves-
tigated because the doses of 10 and 20 mg kg21 i.p. produced
the same degree of behavioral impairment. The maximum
amnesic effect obtained was of the same intensity of that
produced by scopolamine (1 mg kg21 i.p.) and dicyclomine (2
mg kg21 i.p.), used as reference drugs (fig. 1).
Prevention of deficits in passive avoidance behavior
by 5-HT4 agonists. The deficits in passive avoidance behav-
ior induced by the 5-HT4 antagonists SDZ 205557 (10 mg
kg21 i.p.) and GR 125487 (10 mg kg21 i.p.) was prevented, in
the mouse passive avoidance test, by pretreatment with the
5-HT4 agonists BIMU 1 (20 mg kg
21 i.p.) and BIMU 8 (30 mg
kg21 i.p.), injected 20 min before the training session. Both
5-HT4 agonists enhanced the entrance latency up to a value
comparable to that produced by control animals (fig. 2).
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BIMU 1 and BIMU 8, at 5 and 10 mg kg21 i.p. respectively,
were completely ineffective (fig. 2).
BIMU 1 (10 mg kg21 i.p.; 25 mg/mouse i.c.v.) and BIMU 8
(30 mg kg21 i.p.; 30 mg/mouse i.c.v.) were also able to com-
pletely prevent scopolamine (1 mg kg21 i.p.; figs. 3 and 4) and
dicyclomine (2 mg kg21 i.p.; fig. 5) induced deficits in passive
avoidance behavior. The doses of 3 mg kg21 i.p. and 10 mg
i.c.v. BIMU 1 and the doses of 20 mg kg21 i.p. and 10 mg i.c.v.
BIMU 8 were unable to protect against scopolamine-induced
(figs. 3 and 4) and dicyclomine-induced deficits in passive
avoidance behavior (fig. 5).
Exposure to a hypoxic environment produced deficits in
passive avoidance behavior that were completely prevented
by pretreatment with the two 5-HT4 agonists BIMU 1 and
BIMU 8 at the doses of 10 and 30 mg kg21 i.p. respectively
(fig. 6).
The antiamnesic effect produced by i.p. injection of BIMU
1 and BIMU 8 was comparable to that produced by the well
known nootropic drug piracetam (30 mg kg21 i.p.) and the
cholinesterase inhibitor physostigmine (0.2 mg kg21 i.p.) as
illustrated in figures 3, 5 and 6.
Doses of BIMU 1 and BIMU 8 higher than 10 and 30 mg
kg21 i.p., respectively, were not investigated because a com-
plete prevention of scopolamine-, dicyclomine- and hypoxia-
induced deficits in passive avoidance behavior used was al-
ready reached.
BIMU 1 and BIMU 8, when given alone, at the highest
doses used, had no effect on mouse passive avoidance test in
comparison with saline-treated mice (fig. 3). No statistically
significant difference among the entrance latencies for each
compound tested in the training session of the passive avoid-
ance test was observed (data not shown). Table 1 reports the
Fig. 1. Effect of SDZ 205557 and GR 125487 in comparison with scopol-
amine (scop.) and dicyclomine (dicyc.) in mouse passive avoidance test.
All drugs were injected i.p. immediately after punishment. Inside the
column is the number of mice. *P , .01 in comparison with saline-treated
mice.
Fig. 2. Effect of BIMU 1 and BIMU 8 on amnesia induced by both SDZ
205557 (10 mg kg21 i.p.) and GR 125487 (10 mg kg21 i.p.) in mouse
passive-avoidance test. BIMU 1 and BIMU 8 were administered 20 min
before training session although SDZ 205557 and GR 125487 were in-
jected immediately after punishment. All drugs were injected i.p. Inside
the column is the number of mice. *P , .01 in comparison with mice
treated with SDZ 205557 or GR 125487.
Fig. 3. Effect of BIMU 1 and BIMU 8 in comparison with both piracetam
and physostigmine on amnesia induced by scopolamine (1 mg kg21 i.p.) in
the mouse passive avoidance test. BIMU 1, BIMU 8, piracetam and
physostigmine were administered 20 min before training session al-
though scopolamine was injected immediately after punishment. All
drugs were injected i.p. Inside the column is the number of mice. *P , .01
in comparison with mice treated with scopolamine.
Fig. 4. Effect of BIMU 1 and BIMU 8 administered i.c.v. on amnesia
induced by scopolamine (1 mg kg21 i.p.) in the mouse passive avoidance
test. BIMU 1 and BIMU 8 were administered 20 min before training
session. Inside the column is the number of mice. *P , .01 in comparison
with mice treated with scopolamine.
1998 5-HT4 Modulation of Memory 1117







entrance latency values in the training and retention ses-
sions for BIMU 1, BIMU 8, SDZ 205557 and GR 125487 at
the highest effective doses, taken as an example.
Lack of effect by the 5-HT3 antagonist ondansetron.
Ondansetron, up to the dose of 1 mg kg21 i.p., was not able to
prevent scopolamine (1 mg kg21 i.p.), SDZ 205557 (10 mg
kg21 i.p.) and hypoxia-induced deficits in passive avoidance
behavior (fig. 7).
Effect of 5-HT4 agonists and antagonists on mouse
rota rod, Animex and hole board tests. It should be noted
that the 5-HT4 agonists and antagonists we investigated
elicited their modulatory effect on cognitive processes with-
out changing either gross behavior or motor coordination as
revealed by the rota rod test (fig. 8). None of the drugs,
administered at the highest active doses, increased the num-
ber of falls from the rotating rod in comparison with saline-
and vehicle-treated mice (fig. 8). The number of falls in the
rota rod test progressively decreased because mice learned
how to balance on the rotating rod.
The spontaneous motility and inspection activity of mice
was unmodified by administration of the above-mentioned
5-HT4 modulators as revealed by the Animex (fig. 9) and hole
board (fig. 10) tests in comparison with saline-treated mice.
In the hole board test D-amphetamine (6 mg/mouse i.c.v.),
used as a reference drug, increased both parameters evalu-
ated. Because both i.p. and i.c.v. administration of BIMU 1
and BIMU 8 prevented deficits in passive avoidance behav-
ior, the effect of the two 5-HT4 agonists on mouse locomotor
activity was evaluated after i.p. (Animex, fig. 9) and i.c.v.
(hole board, fig. 10) injection.
Fig. 6. Effect of BIMU 1 and BIMU 8 in comparison with both piracetam
and physostigmine on amnesia induced by hypoxia (O2 5% 1 N2 95%) in
the mouse passive avoidance test. BIMU 1, BIMU 8, piracetam and
physostigmine were administered 20 min before training. Mice were
submitted to hypoxia immediately before punishing. All drugs were in-
jected i.p. Inside the column is the number of mice. *P , .01 in compar-
ison with mice submitted to hypoxia.
Fig. 7. Effect of ondansetron on amnesia induced by SDZ 205557 (10 mg
kg21 i.p.) scopolamine (1 mg kg21 i.p.) and hypoxia (O2 5% 1 N2 95%) in
mouse passive-avoidance test. Ondansetron was administered 20 min
before training session although SDZ 205557 and scopolamine were in-
jected immediately after punishment. Mice were submitted to hypoxia
immediately before punishing. All drugs were injected i.p. Inside the
column is the number of mice.
Fig. 5. Effect of BIMU 1 and BIMU 8 in comparison with both piracetam
and physostigmine on amnesia induced by dicyclomine (2 mg kg21 i.p.) in
the mouse passive avoidance test. BIMU 1, BIMU 8, piracetam and
physostigmine were administered 20 min before training session al-
though dicyclomine was injected immediately after punishment. All
drugs were injected i.p. Inside the column is the number of mice. *P , .01
in comparison with mice treated with dicyclomine.
TABLE 1






Latency To Enter The Dark
Compartment(s)
Training Retention
Saline Saline 18.4 6 2.3 98.8 6 7.5
BIMU 1 10 Saline 16.9 6 2.1 95.9 6 7.3
BIMU 8 30 Saline 18.1 6 1.9 93.0 6 8.5
Piracetam 30 Saline 19.2 6 2.0 86.9 6 8.2
Physostigmine 0.2 Saline 17.9 6 2.2 99.7 6 7.9
Saline SDZ 205557 10 18.7 6 3.1 55.8 6 9.2a
Saline GR 125487 20 20.3 6 2.9 58.1 6 8.1a
Saline Scopolamine 1 19.7 6 2.6 57.5 6 8.3a
Saline Dicyclomine 2 19.8 6 1.5 53.1 6 9.4a
Pretreatment and treatment drugs were administered, respectively, 20 min be-
fore and immediately after the training session. The number of mice ranged between
18 and 25.
a P , .01 vs. saline-treated mice.
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5-HT4 receptors appear to be involved in the regulation of
cognitive processes in mice. Our results demonstrate that the
administration of 5-HT4 receptor antagonists (SDZ 205557,
GR 125487) provoke amnesia in the mouse passive avoidance
test of severity comparable to that induced by the amnesic
drugs scopolamine and dicyclomine. The 5-HT4 receptor ago-
nists (BIMU 1, BIMU 8) are able to prevent the amnesia
induced not only by 5-HT4 receptor antagonists, but also by
antimuscarinic drugs and exposure to a hypoxic environ-
ment. Previous data, demonstrating the amelioration in rats
of social olfactory memory (Letty et al., 1997) and associative
memory (Marchetti-Gauthier et al., 1997) produced by the
5-HT4 agonist BIMU 1, confirmed our results.
BIMU 1 and BIMU 8 have been reported to be endowed
also with 5-HT3 receptor antagonistic activity (Turconi et al.,
1990, 1991). However, their procognitive effect seems unre-
lated to the blockade of 5-HT3 receptors because ondanse-
tron, a highly selective 5-HT3 receptor antagonist (Turconi et
al., 1991), did not exert any effect on hypoxia-, scopolamine-
and 5-HT4 antagonists-induced amnesia. The lack of im-
provement of social olfactory memory in rats by ondansetron
(Letty et al., 1997) confirms the hypothesis that 5-HT3 recep-
tors are not involved in the regulation of memory processes.
5-HT4 receptors have a restricted distribution in guinea
pig and human brains, suggesting that they have specific
functions and indicating that they play a role in neuronal
excitability and neurotransmitter release. Rat interpeduncu-
lar nucleus, thalamus and hippocampus contain a high de-
gree of 5-HT4 receptors (Waeber et al., 1993). At the hip-
pocampal level the distribution is clearly laminar along the
pyramidal cell layers CA1, CA2, CA3 and dentate gyrus
(Waeber et al., 1993). In the human brain 5-HT4 receptors
have been observed in the frontal cortex, superior colliculi,
limbic structures and basal ganglia (Waeber et al., 1993;
Grossman et al., 1993). A high density of 5-HT4 receptors
have been observed especially in the nigro-striatal pathway
and hippocampus (Waeber et al., 1993). The location of 5-HT4
receptors in the hippocampus from several species is also
consistent with a role for the receptor in cognitive processes
(Bockaert et al., 1994a; Letty et al., 1997; Marchetti-Gautier
et al., 1997; Fontana et al., 1997). 5-HT4 receptor activation
has been found to inhibit after-hyperpolarization in rat CA1
hippocampal neurones and such effects may contribute to the
induction of long-term potentiation, an elementary biochem-
ical and cellular process for learning and memory (Andrade
Fig. 8. Lack of effect of BIMU 1, BIMU 8, SDZ 205557 and GR 125487 on
mouse rota rod test. *P , .01 in comparison with saline controls. Each
point represents the mean of 10 mice.
Fig. 9. Lack of effect by BIMU 1, BIMU 8, SDZ 205557 and GR 125487 in
mouse Animex test. Each column represents the mean of 15 mice.
Fig. 10. Lack of effect of BIMU 1 and BIMU 8 administered i.c.v. in
comparison with amphetamine in the mouse hole board test. Test was
performed between 15 and 20 min after administration. Each column
represents the mean of 10 mice. *P , .01 in comparison with saline
controls.
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and Chaput, 1991). In mouse colliculi neurones, moreover,
5-HT4 receptor agonism elevates intracellular adenylyl cy-
clase and, consequently, inhibits voltage-sensitive potassium
channel opening time (Dumuis et al., 1989; Andrade and
Chaput, 1991; Bockaert et al., 1994a, b). Prolonged closure of
potassium channels, and thus neuronal hyperexcitability,
was seen even after very short exposure to 5-HT (Bockaert et
al., 1994b). These mechanisms may be involved in the induc-
tion of hippocampal CA1 late stage long-term potentiation
(Frey et al., 1993), a potential mechanism for explicit forms of
memory. Furthermore, a marked loss of 5-HT4 receptors,
labeled with [3H]-GR 113808, in hippocampal and cortical
regions in the brains of patients with Alzheimer’s disease
(Reynolds et al., 1995) supports the hypothesis of a role for
5-HT4 receptors in memory processes.
An in vivo study indicated that i.c.v. injection of zacopride
and renzapride, two 5-HT4 agonists, increased the energy of
low frequency hippocampal theta rhythm and other fre-
quency bands (Boddeke and Kalkman, 1990). These effects
were blockaded by scopolamine, suggesting a cholinergic step
in the effects of 5-HT4 agonists. The involvement of the
cholinergic system in the central effects of 5-HT4 agonists
was confirmed by rat microdialysis studies in which an in-
crease in ACh extracellular levels was observed after BIMU
1 and BIMU 8 administration (Consolo et al., 1994). Further-
more, Ghelardini et al. (1996) demonstrated that the antino-
ciceptive effect of BIMU 1 and BIMU 8 is mediated via
activation of cholinergic neurotransmission. Because it has
long been known that the stimulation of the cholinergic sys-
tem improves cognitive processes (Coyle, 1995) the facilita-
tory effect induced by the 5-HT4 agonists BIMU 1 and BIMU
8 could be due, at least in part, to activation of the cholinergic
system.
BIMU 1 and BIMU 8 exerted their antiamnesic effect by
acting centrally. It was possible to reach the same intensity
of analgesia by injecting directly into the cerebral ventricles
doses (25–30 mg/mouse) of BIMU 1 and BIMU 8 which were
much lower than those needed parenterally. This finding
excludes the possibility that the antiamnesic action can de-
pend on retrodiffusion of the two 5-HT4 agonists from the
cerebral ventricles to the periphery.
The 5-HT4 receptor agonists BIMU 1 and BIMU 8 have
been reported to be endowed with analgesic properties (Ghe-
lardini et al., 1996). In our experimental conditions these
compounds were administered before receiving the punish-
ing stimulus in correspondence with their maximum antino-
ciceptive activity. It is, however, unlikely that their analgesic
effect may have influenced the results obtained. Analgesic
drugs, by reducing the perception of the punishing stimulus
(electric shock), may produce a false amnesic effect. BIMU 1
and BIMU 8, even at the highest doses used, were always
able to prevent amnesia indicating that the degree of antino-
ciception produced was insufficient to reduce the perception
of the electric shock applied.
The 5-HT4 receptor agonists and antagonists, at the high-
est doses used, did not modify the animals’ gross behavior.
Nor did these compounds impair motor coordination as re-
vealed by the rota rod test or modify locomotor and inspection
activity as indicated by the hole board and Animex tests. We
can, thus, suppose that the effects produced by 5-HT4 recep-
tor modulators were not imputable to compromised viability.
Higher doses of all compounds were not investigated because
the maximum amnesic (SDZ 205557, GR 125487) and anti-
amnesic (BIMU 1, BIMU 8) effect was already reached.
In conclusion, these results indicate the important role
played by 5-HT4 receptors in the regulation of memory pro-
cesses. On these bases, the 5-HT4 receptor agonists could be
useful in the treatment of cognitive deficits although 5-HT4
receptor antagonists may represent pharmacological tools for
investigation of new potential antiamnesic drugs.
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